-+ 0.00%
-+ 0.00%
-+ 0.00%

Aprea Therapeutics To Present Abstract Titled 'Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)' At 2026 American Society Of Clinical Oncology Annual Meeting

Benzinga·04/21/2026 14:20:57
Listen to the news

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract "Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)" at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago, IL.